For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for HeartFlow, Inc. (HTFL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
HeartFlow, Inc.
HTFL NASDAQHeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions. It transforms coronary computed tomography angiography (CCTA) scans into detailed 3D models of patients' coronary arteries, enabling non-invasive assessment of coronary artery disease (CAD). Key products include Roadmap Analysis for efficient CAD detection, FFRCT Analysis to evaluate blood flow and revascularization needs, and Plaque Analysis to quantify and characterize plaque for risk assessment and disease management. The integrated HeartFlow One platform supports clinicians in identifying, deciding, and managing CAD, optimizing patient care pathways with personalized insights. HeartFlow also provides comprehensive support services, including clinical, operational, technical, and financial resources to help institutions build scalable CCTA programs. Headquartered in Redwood City, California, the company plays a pivotal role in advancing proactive, patient-centered coronary care by empowering healthcare providers with innovative tools to detect, understand, and treat CAD effectively.
Earnings Schedule
Checked daily · calendar updated Aug 13| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| May 14, 2026 | $-0.17 | $-0.16 +5.9% | — | — |
| Mar 18, 2026 | $-0.16 | $-0.12 +25.0% | — | — |
| Nov 12, 2025 | $-0.24 | $-0.27 -12.5% | — | — |
| Oct 8, 2025 | $0.04 | $0.04 +0.0% | — | — |
| Sep 19, 2025 | $-0.21 | $-1.10 -423.8% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 12, 2026 | 4 | View |
| Aug 10, 2026 | 4 | View |
| Aug 10, 2026 | 4 | View |
| Aug 10, 2026 | 4 | View |
| Aug 10, 2026 | 4 | View |
| Aug 10, 2026 | 144 | View |
| Aug 6, 2026 | SCHEDULE 13G/A | View |
| Jul 31, 2026 | 4 | View |
| Jul 28, 2026 | 4 | View |
| Jul 28, 2026 | 4 | View |
| Jul 28, 2026 | SCHEDULE 13G | View |
| Jul 24, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 13, 2026 2:55pm (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -3.17
Total Equity: $300.65M
Shares: 36,853,867
Total Debt: $0.00
Cash: $44.78M
EBITDA: -$58.63M
Total Debt: $0.00
Cash: $44.78M
Revenue: $176.03M
Shares: 36,853,867
Revenue: $176.03M
Revenue: $176.03M
Revenue: $176.03M
Total Equity: $300.65M
Tax Rate: 0.1%
Equity: $300.65M
Total Debt: $0.00
Cash: $44.78M
Current Liabilities: $42.37M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $300.65M
Shares: 36,853,867
Shares: 36,853,867
CapEx: -$5.03M
Shares: 36,853,867
Stock Price: $29.75
Net Income: -$116.79M
Income Statement (Annual)
Last updated: Aug 10, 2026 10:21am (3d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $87.2M | $125.8M | $176.0M |
| Cost of Revenue | $29.1M | $31.4M | $40.8M |
| Gross Profit | $58.1M | $94.4M | $135.2M |
| Operating Expenses | $131.0M | $155.7M | $199.3M |
| Operating Income | -$72.9M | -$61.2M | -$64.1M |
| Net Income | -$95.7M | -$96.4M | -$116.8M |
| EBITDA | -$68.2M | -$55.9M | -$58.6M |
| EPS | $-25.32 | $-17.98 | $-3.17 |
| EPS (Diluted) | $-25.32 | $-17.98 | $-3.17 |
Balance Sheet (Annual)
Last updated: Aug 10, 2026 10:21am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Cash & Equivalents | — | $122.8M | $51.4M | $44.8M |
| Total Current Assets | — | — | $82.3M | $220.2M |
| Total Assets | — | — | $118.7M | $359.5M |
| Current Liabilities | — | — | $33.6M | $42.4M |
| Long-Term Debt | — | — | — | — |
| Total Liabilities | — | — | $209.6M | $58.8M |
| Total Equity | -$693.6M | -$777.6M | -$90.9M | $300.6M |
| Retained Earnings | — | -$1.1M | -$971.0M | -$1.1B |
Cash Flow (Annual)
Last updated: Aug 10, 2026 10:21am (3d ago)| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -$76.4M | -$69.0M | -$54.0M |
| Capital Expenditure | -$6.1M | -$4.4M | -$5.0M |
| Free Cash Flow | -$82.5M | -$73.4M | -$59.0M |
| Acquisitions (net) | — | — | — |
| Net Debt Issued / (Repaid) | — | — | -$115.1M |
| Dividends Paid | — | — | — |
| Stock Buybacks | $-228,000 | — | — |
| Net Change in Cash | $86.3M | -$71.4M | -$6.4M |
Growth Trends (YoY %)
Last updated: Aug 10, 2026 10:21am (3d ago)| Metric | 2024 | 2025 |
|---|---|---|
| Revenue Growth | +44.3% | +39.9% |
| Gross Profit Growth | +62.7% | +43.1% |
| Operating Income Growth | +16.0% | -4.6% |
| Net Income Growth | -0.8% | -21.1% |
| EBITDA Growth | +18.1% | -4.9% |
Insider Trading (Recent)
All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-30 | Farquhar John C.M. | M-OptionExercise | 2,789.00 | $0.00 | $0 |
| 2026-07-30 | Farquhar John C.M. | M-OptionExercise | 18,694.00 | $0.00 | $0 |
| 2026-07-30 | Farquhar John C.M. | M-OptionExercise | 9,737.00 | $0.00 | $0 |
| 2026-07-27 | Verghese Vikram | M-OptionExercise | 22,522.00 | $0.00 | $0 |
| 2026-07-24 | Lightcap Jeffrey C | M-OptionExercise | 47,420.00 | $0.00 | $0 |
| 2026-07-22 | BARABE TIMOTHY C | M-OptionExercise | 3,710.00 | $0.00 | $0 |
| 2026-07-21 | Verghese Vikram | M-OptionExercise | 22,522.00 | $0.00 | $0 |
| 2026-07-17 | BARABE TIMOTHY C | M-OptionExercise | 5,000.00 | $0.00 | $0 |
| 2026-07-15 | Rogers Campbell | M-OptionExercise | 9,219.00 | $0.00 | $0 |
| 2026-07-15 | Rogers Campbell | S-Sale | 9,219.00 | $25.72 | $237,113 |
| 2026-07-10 | Farquhar John C.M. | S-Sale | 22,562.00 | $27.75 | $626,096 |
| 2026-07-08 | WELDON WILLIAM C | M-OptionExercise | 17,123.00 | $0.00 | $0 |
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Claude Reading
ai-findings step) when a report is run on this ticker.
GPT Reading
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.